image

Investors

Corporate Profile

Nurix Therapeutics is a biopharmaceutical company focused on the discovery, development, and commercialization of small molecule therapies designed to modulate cellular protein levels as a novel treatment approach for cancer and other challenging diseases. Leveraging Nurix’s extensive expertise in E3 ligases together with its proprietary DNA-encoded libraries, Nurix has built DELigase, an integrated discovery platform to identify and advance novel drug candidates that can modulate proteins within the cell.

Archived Events
Baird Global Healthcare Conference
September 12, 2023 at 12:45 PM EDT
View Webcast
Wells Fargo Healthcare Conference
September 7, 2023 at 3:00 PM EDT
View Webcast
Corporate Update
September 7, 2023 at 8:30 AM EDT
View Webcast
RBC Capital Markets 2023 Global Healthcare Conference
May 17, 2023 at 4:35 PM EDT
View Webcast
22nd Annual Needham Virtual Healthcare
April 20, 2023 at 3:00 PM EDT
View Webcast
Oppenheimer 33rd Annual Healthcare Conference
March 14, 2023 from 10:40 AM to 11:10 AM EDT
View Webcast
Wells Fargo Targeted Protein Degradation Virtual Summit
February 21, 2023 from 1:00 PM to 1:45 PM EST
View Webcast
Wells Fargo Targeted Protein Degradation Virtual Summit
February 21, 2023 from 8:00 AM to 8:45 AM EST
View Webcast
SVB Securities Global Biopharma Conference
February 15, 2023 from 4:20 PM to 5:00 PM EST
View Webcast
Corporate Presentations
Scientific Presentation
Print Page
Email Alerts
RSS Feeds
Contact IR